{"disease":{"id":"alk-anaplastic-large-cell-lymphoma","name":"alk anaplastic large cell lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT00585195","title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04058470","title":"Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT01979536","title":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06176690","title":"Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT05934045","title":"Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT03493451","title":"Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT01035463","title":"Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT02978625","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02561273","title":"Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT03113500","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT04476459","title":"Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT04796857","title":"Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT02465528","title":"Ceritinib Rare Indications Study in ALK+ Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03707847","title":"Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Mingzhi Zhang","has_results":false},{"nct_id":"NCT01254578","title":"Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03075553","title":"Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT02462538","title":"Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","has_results":false},{"nct_id":"NCT04260009","title":"Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02729961","title":"Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Washington","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}